Literature DB >> 19079217

CD4+ T-cell loss and delayed expression of modulators of immune responses at mucosal sites of vaccinated macaques following SIV(mac251) infection.

M Vaccari1, A Boasso, Z-M Ma, V Cecchinato, D Venzon, M N Doster, W P Tsai, G M Shearer, D Fuchs, B K Felber, G N Pavlakis, C J Miller, G Franchini.   

Abstract

Systemic immunization of macaques with a combination of DNA-poxvirus-based vaccines confers protection from high level of both systemic and mucosal viral replication following rectal exposure to the pathogenic SIV(mac251). Here we investigated early post-infection events in rectal and vaginal tissues, and found that the loss of CCR5+CD4+ T cells was equivalent in vaccinated and control macaques, despite a three logs reduction at mucosal sites of simian immunodeficiency virus (SIV) RNA in the vaccinated group. Even though a normal CD4+ T cell number is not reconstituted at mucosal sites in either group, vaccination appeared to confer a better preservation of the CD4+ CCR5+ T cells that replenish these sites. Analysis of rectal tissues RNA following challenge exposure demonstrated a decreased expression in vaccinated macaques of transforming growth factor-beta, cytotoxic T lymphocyte antigen-4, FoxP3, and indoleamine 2,3-dioxygenase, an immune suppressive enzyme expressed by dendritic cells that converts tryptophan to kynurenine and limits T-cell responses. Accordingly, the ratio of kynurenine and tryptophan in the plasma was significantly reduced in the vaccinated animals respect to the controls. Thus, preexisting adaptive immune responses induced by these vaccine modalities, although they do not protect from CD4+ T-cell depletion, nevertheless, they contain SIV(mac251) replication and delay expression of markers of T-cell activation and/or suppression at mucosal sites.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19079217      PMCID: PMC7251643          DOI: 10.1038/mi.2008.60

Source DB:  PubMed          Journal:  Mucosal Immunol        ISSN: 1933-0219            Impact factor:   7.313


  43 in total

1.  Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

Authors:  R R Amara; F Villinger; J D Altman; S L Lydy; S P O'Neil; S I Staprans; D C Montefiori; Y Xu; J G Herndon; L S Wyatt; M A Candido; N L Kozyr; P L Earl; J M Smith; H L Ma; B D Grimm; M L Hulsey; J Miller; H M McClure; J M McNicholl; B Moss; H L Robinson
Journal:  Science       Date:  2001-04-06       Impact factor: 47.728

2.  Vaccine-induced CD8+ central memory T cells in protection from simian AIDS.

Authors:  Monica Vaccari; Christopher J Trindade; David Venzon; Maurizio Zanetti; Genoveffa Franchini
Journal:  J Immunol       Date:  2005-09-15       Impact factor: 5.422

3.  NASBA technology: isothermal RNA amplification in qualitative and quantitative diagnostics.

Authors:  J W Romano; K G Williams; R N Shurtliff; C Ginocchio; M Kaplan
Journal:  Immunol Invest       Date:  1997 Jan-Feb       Impact factor: 3.657

4.  Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection.

Authors:  Joseph J Mattapallil; Daniel C Douek; Brenna Hill; Yoshiaki Nishimura; Malcolm Martin; Mario Roederer
Journal:  Nature       Date:  2005-04-28       Impact factor: 49.962

5.  Potentiation of simian immunodeficiency virus (SIV)-specific CD4(+) and CD8(+) T cell responses by a DNA-SIV and NYVAC-SIV prime/boost regimen.

Authors:  Z Hel; W P Tsai; A Thornton; J Nacsa; L Giuliani; E Tryniszewska; M Poudyal; D Venzon; X Wang; J Altman; D I Watkins; W Lu; A von Gegerfelt; B K Felber; J Tartaglia; G N Pavlakis; G Franchini
Journal:  J Immunol       Date:  2001-12-15       Impact factor: 5.422

6.  CCR5- and CXCR4-tropic HIV-1 are equally cytopathic for their T-cell targets in human lymphoid tissue.

Authors:  J C Grivel; L B Margolis
Journal:  Nat Med       Date:  1999-03       Impact factor: 53.440

7.  Reduced protection from simian immunodeficiency virus SIVmac251 infection afforded by memory CD8+ T cells induced by vaccination during CD4+ T-cell deficiency.

Authors:  Monica Vaccari; Joseph Mattapallil; Kaimei Song; Wen-Po Tsai; Anna Hryniewicz; David Venzon; Maurizio Zanetti; Keith A Reimann; Mario Roederer; Genoveffa Franchini
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

8.  Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy.

Authors:  Moraima Guadalupe; Elizabeth Reay; Sumathi Sankaran; Thomas Prindiville; Jason Flamm; Andrew McNeil; Satya Dandekar
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

9.  Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses.

Authors:  Zdenek Hel; Janos Nacsa; Elzbieta Tryniszewska; Wen-Po Tsai; Robyn Washington Parks; David C Montefiori; Barbara K Felber; James Tartaglia; George N Pavlakis; Genoveffa Franchini
Journal:  J Immunol       Date:  2002-11-01       Impact factor: 5.422

10.  Analysis of Gag-specific cytotoxic T lymphocytes in simian immunodeficiency virus-infected rhesus monkeys by cell staining with a tetrameric major histocompatibility complex class I-peptide complex.

Authors:  M J Kuroda; J E Schmitz; D H Barouch; A Craiu; T M Allen; A Sette; D I Watkins; M A Forman; N L Letvin
Journal:  J Exp Med       Date:  1998-05-04       Impact factor: 14.307

View more
  20 in total

1.  Fatal pancreatitis in simian immunodeficiency virus SIV(mac251)-infected macaques treated with 2',3'-dideoxyinosine and stavudine following cytotoxic-T-lymphocyte-associated antigen 4 and indoleamine 2,3-dioxygenase blockade.

Authors:  Monica Vaccari; Adriano Boasso; Claudio Fenizia; Dietmar Fuchs; Anna Hryniewicz; Tia Morgan; Deborah Weiss; Melvin N Doster; Jean Michel Heraud; Gene M Shearer; Genoveffa Franchini
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

2.  Regulatory and Helper Follicular T Cells and Antibody Avidity to Simian Immunodeficiency Virus Glycoprotein 120.

Authors:  Matthew J Blackburn; Ma Zhong-Min; Francesca Caccuri; Katherine McKinnon; Luca Schifanella; Yongjun Guan; Giacomo Gorini; David Venzon; Claudio Fenizia; Nicolò Binello; Shari N Gordon; Christopher J Miller; Genoveffa Franchini; Monica Vaccari
Journal:  J Immunol       Date:  2015-08-21       Impact factor: 5.422

3.  Comparison of systemic and mucosal vaccination: impact on intravenous and rectal SIV challenge.

Authors:  D L Bolton; K Song; R L Wilson; P A Kozlowski; G D Tomaras; B F Keele; R V Lovingood; S Rao; M Roederer
Journal:  Mucosal Immunol       Date:  2011-10-26       Impact factor: 7.313

4.  Vaccine induced antibodies to the first variable loop of human immunodeficiency virus type 1 gp120, mediate antibody-dependent virus inhibition in macaques.

Authors:  Izabela Bialuk; Stephen Whitney; Vibeke Andresen; Ruth H Florese; Janos Nacsa; Valentina Cecchinato; Valerio W Valeri; Jean-Michel Heraud; Shari Gordon; Robyn Washington Parks; David C Montefiori; David Venzon; Thorsten Demberg; Marjorie Robert- Guroff; Gary Landucci; Donald N Forthal; Genoveffa Franchini
Journal:  Vaccine       Date:  2011-10-27       Impact factor: 3.641

5.  TRIM5α does not affect simian immunodeficiency virus SIV(mac251) replication in vaccinated or unvaccinated Indian rhesus macaques following intrarectal challenge exposure.

Authors:  Claudio Fenizia; Brandon F Keele; David Nichols; Stefano Cornara; Nicolò Binello; Monica Vaccari; Poonam Pegu; Marjorie Robert-Guroff; Zhong-Min Ma; Christopher J Miller; David Venzon; Vanessa Hirsch; Genoveffa Franchini
Journal:  J Virol       Date:  2011-09-14       Impact factor: 5.103

6.  Antibodies to gp120 and PD-1 expression on virus-specific CD8+ T cells in protection from simian AIDS.

Authors:  Monica Vaccari; Rabih Halwani; L Jean Patterson; Adriano Boasso; Jennifer Beal; Elzbieta Tryniszewska; Anna Hryniewicz; David Venzon; Elias K Haddad; Mohamed El-Far; Margherita Rosati; George N Pavlakis; Barbara K Felber; Saleh Al-Muhsen; Marjorie Robert-Guroff; Rafick-Pierre Sekaly; Genoveffa Franchini
Journal:  J Virol       Date:  2013-01-16       Impact factor: 5.103

7.  Protection afforded by an HIV vaccine candidate in macaques depends on the dose of SIVmac251 at challenge exposure.

Authors:  Monica Vaccari; Brandon F Keele; Steven E Bosinger; Melvin N Doster; Zhong-Min Ma; Justin Pollara; Anna Hryniewicz; Guido Ferrari; Yongjun Guan; Donald N Forthal; David Venzon; Claudio Fenizia; Tia Morgan; David Montefiori; Jeffrey D Lifson; Chris J Miller; Guido Silvestri; Margherita Rosati; Barbara K Felber; George N Pavlakis; James Tartaglia; Genoveffa Franchini
Journal:  J Virol       Date:  2013-01-16       Impact factor: 5.103

Review 8.  Use of nonhuman primate models to develop mucosal AIDS vaccines.

Authors:  Meritxell Genescà; Christopher J Miller
Journal:  Curr HIV/AIDS Rep       Date:  2010-02       Impact factor: 5.071

9.  A vaccine encoding conserved promiscuous HIV CD4 epitopes induces broad T cell responses in mice transgenic to multiple common HLA class II molecules.

Authors:  Susan Pereira Ribeiro; Daniela Santoro Rosa; Simone Gonçalves Fonseca; Eliane Conti Mairena; Edilberto Postól; Sergio Costa Oliveira; Luiza Guilherme; Jorge Kalil; Edecio Cunha-Neto
Journal:  PLoS One       Date:  2010-06-11       Impact factor: 3.240

10.  Treatment with anti-FasL antibody preserves memory lymphocytes and virus-specific cellular immunity in macaques challenged with simian immunodeficiency virus.

Authors:  Bhawna Poonia; Maria S Salvato; Hideo Yagita; Toshihiro Maeda; Ko Okumura; C David Pauza
Journal:  Blood       Date:  2009-06-04       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.